Skip to main content

KMT2A/MLL Products

The MLL gene encodes a DNA-binding protein that methylates histone H3 (see MIM 601128) lys4 (H3K4) and positively regulates expression of target genes, including multiple HOX genes (see MIM 142980). MLL is a frequent target for recurrent translocations in acute leukemias that may be characterized as acute myeloid leukemia (AML; MIM 601626), acute lymphoblastic leukemia (ALL), or mixed lineage (biphenotypic) leukemia (MLL). Leukemias with translocations involving MLL possess unique clinical and biologic characteristics and are often associated with poor prognosis. MLL rearrangements are found in more than 70% of infant leukemias, whether the immunophenotype is more consistent with ALL or AML6, but are less frequent in leukemias from older children. MLL translocations are also found in approximately 10% of AMLs in adults, as well as in therapy-related leukemias, most often characterized as AML, that develop in patients previously treated with topoisomerase II inhibitors for other malignancies. More than 50 different MLL fusion partners have been identified. Leukemogenic MLL translocations encode MLL fusion proteins that have lost H3K4 methyltransferase activity. A key feature of MLL fusion proteins is their ability to efficiently transform hematopoietic cells into leukemia stem cells (Krivtsov and Armstrong, 2007 (PubMed 17957188)).(supplied by OMIM)
Show More

125 results for "KMT2A/MLL" in Products

125 results for "KMT2A/MLL" in Products

KMT2A/MLL Products

The MLL gene encodes a DNA-binding protein that methylates histone H3 (see MIM 601128) lys4 (H3K4) and positively regulates expression of target genes, including multiple HOX genes (see MIM 142980). MLL is a frequent target for recurrent translocations in acute leukemias that may be characterized as acute myeloid leukemia (AML; MIM 601626), acute lymphoblastic leukemia (ALL), or mixed lineage (biphenotypic) leukemia (MLL). Leukemias with translocations involving MLL possess unique clinical and biologic characteristics and are often associated with poor prognosis. MLL rearrangements are found in more than 70% of infant leukemias, whether the immunophenotype is more consistent with ALL or AML6, but are less frequent in leukemias from older children. MLL translocations are also found in approximately 10% of AMLs in adults, as well as in therapy-related leukemias, most often characterized as AML, that develop in patients previously treated with topoisomerase II inhibitors for other malignancies. More than 50 different MLL fusion partners have been identified. Leukemogenic MLL translocations encode MLL fusion proteins that have lost H3K4 methyltransferase activity. A key feature of MLL fusion proteins is their ability to efficiently transform hematopoietic cells into leukemia stem cells (Krivtsov and Armstrong, 2007 (PubMed 17957188)).(supplied by OMIM)
Show More
Applications: IHC, WB, IP
Reactivity: Human, Mouse
Applications: WB, Flow, IP, Simple Western, ChIP
Reactivity: Human
Applications: WB, IP
Reactivity: Human
Applications: WB, IP
Reactivity: Human

Recombinant Monoclonal Antibody.

Applications: ICC/IF, Func
Reactivity: Human
Applications: WB, IP
Reactivity: Human

Recombinant Monoclonal Antibody.

Applications: AC
Applications: WB, Flow, IP, Simple Western, ChIP
Reactivity: Human
Applications: WB, IP
Reactivity: Human
Applications: IHC, WB, IP
Reactivity: Human, Mouse
Applications: IHC, WB, IP
Reactivity: Human, Mouse
Applications: WB, Flow, IP, Simple Western, ChIP
Reactivity: Human
Applications: WB, Flow, IP, Simple Western, ChIP
Reactivity: Human
Applications: WB, IP
Reactivity: Human

Recombinant Monoclonal Antibody.

Applications: WB, IP
Reactivity: Human
Applications: WB, IP
Reactivity: Human
Applications: WB, IP
Reactivity: Human
Applications: WB, Flow, IP, Simple Western, ChIP
Reactivity: Human
Applications: WB, IP
Reactivity: Human
Applications: WB, Flow, IP, Simple Western, ChIP
Reactivity: Human
Applications: IHC, WB, IP
Reactivity: Human, Mouse
Applications: IHC, WB, IP
Reactivity: Human, Mouse
Applications: WB, IP
Reactivity: Human

Recombinant Monoclonal Antibody.

Applications: WB, IP
Reactivity: Human

Recombinant Monoclonal Antibody.

Applications: IHC, WB, IP
Reactivity: Human, Mouse
Results Per Page
5 10 25 50
/ 5